

CBR1 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP7563b**Specification****CBR1 Antibody (C-term) Blocking Peptide -
Product Information**Primary Accession [P16152](#)**CBR1 Antibody (C-term) Blocking Peptide -
Additional Information**

Gene ID 873

Other Names

Carbonyl reductase [NADPH] 1,
15-hydroxyprostaglandin dehydrogenase
[NADP(+)], NADPH-dependent carbonyl
reductase 1, Prostaglandin 9-ketoreductase,
Prostaglandin-E(2) 9-reductase, CBR1, CBR,
CRN

Target/Specificity

The synthetic peptide sequence used to
generate the antibody [AP7563b](#) was
selected from the C-term region of human
CBR1. A 10 to 100 fold molar excess to
antibody is recommended. Precise
conditions should be optimized for a
particular assay.

Format

Peptides are lyophilized in a solid powder
format. Peptides can be reconstituted in
solution using the appropriate buffer as
needed.

Storage

Maintain refrigerated at 2-8°C for up to 6
months. For long term storage store at
-20°C.

Precautions

This product is for research use only. Not
for use in diagnostic or therapeutic
procedures.

**CBR1 Antibody (C-term) Blocking Peptide -
Protein Information****CBR1 Antibody (C-term) Blocking Peptide -
Background**

Carbonyl reductase 1 (CBR1) is one of several
monomeric, NADPH-dependent oxidoreductases
having wide specificity for carbonyl
compounds. This enzyme is widely distributed
in human tissues.

**CBR1 Antibody (C-term) Blocking Peptide -
References**

Colombe, L., *Exp. Dermatol.* 16 (9), 762-769
(2007) Lakhman, S.S., *Mol. Pharmacol.* 72 (3),
734-743 (2007) Gonzalez-Covarrubias, V., *Drug
Metab. Dispos.* 35 (6), 973-980 (2007)

Name CBR1 ([HGNC:1548](#))

Synonyms CBR, CRN, SDR21C1

Function

NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed:[18449627](http://www.uniprot.org/citations/18449627) target="_blank">18449627, PubMed:[15799708](http://www.uniprot.org/citations/15799708) target="_blank">15799708, PubMed:[17912391](http://www.uniprot.org/citations/17912391) target="_blank">17912391, PubMed:[7005231](http://www.uniprot.org/citations/7005231) target="_blank">7005231). Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed:[18826943](http://www.uniprot.org/citations/18826943) target="_blank">18826943, PubMed:[17344335](http://www.uniprot.org/citations/17344335) target="_blank">17344335).

Cellular Location

Cytoplasm.

Tissue Location

Expressed in kidney (at protein level).

CBR1 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)